|
1 |
1. Абрамова Н.А., Александров А.А., Андреева Е.Н. Эндокринология. Национальное руководство. – Москва ГЭОТАР-Медиа, 2012. – 1072 с. 2. Аметов А.С. Сахарный диабет 2 типа. Про-блемы и решения. – Москва, ГЭОТАР-Медиа, 2013. – 1032 с. 3. Асадов Д.А., Арипов Т.Ю. Клиническое руководство по диагностике, лечению и профилактике сахарного диабета у взрослых в первичном звене здравоохранения. – Ташкент. – 2013. – С. 36-49. 4. Баранов А.А. Беленков Ю.Н. Гусев Е.Н., Денисов И.Н. Клинические рекомендации, стандарты ведения больных – Москва, ГЭОТАР-Медиа, 2006. – 555 с. 5. Дедов И.И., Мельниченко Г.А. Эндокринология. Национальное руководство. – Москва ГЭОТАР-Медиа, 2013. – С. 271-330. 6. Дедов И.И., Мельниченко Г.А. Эндокринология. Клинические рекомендации. – Москва ГЭОТАР-Медиа, 2012. – 368 с. 7. Денисов И.Н. Шевченко Ю.Л. Клинические рекомендации для практикующих врачей, осно-ванные на доказательной медицине. – Москва ГЭОТАР-Медиа, 2003 – 1242 с. 8. Захидова М.З. Сборник клинических протоколов № 4: учебно-методическое пособие для общепрактикующих врачей – Ташкент. 2015 – 360 с. 9. Матвейков Г.П. Клиническая диагностика (справочное пособие для семейного врача). – Минск «Беларусь», 2010. – 350 с. 10. Рахимова Г.Н., Алиханова Н.М., Нармухамедова Н.А., Махмудова М.С. Сборник клинических протоколов по эндокринологии. – Ташкент. – 2015. – С. 17-23. 11. Scottish Intercollegiate Guideline Network. Management of diabetes. A national clinical guideline, March 2010. 12. WHO/EMRO. Guidelines for the prevention, management and care of diabetes mellitus. 2006. 13. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes: prospective observational study. //Br Med J. – 2000. – Vol. 321(7258). – P. 412-421. 14. Kelly T.N., Bazzano L.A., Fonseca V.A., Thethi T.K., Reynolds K., He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. //Ann Intern Med. – 2009. – Vol. 151(6). – P. 394-403. 15. Turnbull F.M., Abraira C., Anderson R.J., Yington R.P., Chalmers J.P., Duckworth W.C., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. //Diabetologia. – 2009. – Vol. 52(11). – P. 2288-2298. 16. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. //Lancet. – 2008. – Vol. 351(9118). – P. 1755-1762. 17. Belch J., MacCuish A., Campbell I., Cobbe S., Taylor R., Prescott R., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. //Br Med J. – 2008. – Vol. 337. – P. 1840. 18. Ogawa H., Nakayama M., Morimoto T., Uemura S., Kanauchi M., Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. //JAMA. – 2008. – Vol. 300(18). – P. 2134-2141. 19. De Berardis G, Sacco M, Strippoli GF, Pelle-grini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. //Br Med J. – 2009. –Vol. 339. – P. 4531. 20. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. //Lancet. – 2004. – Vol. 364(9435). – P. 685-696. 21. Sever P.S., Poulter N.R., Dahlof B., Wedel H., Collins R., Beevers G, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). //Diabetes Care. – 2005. – Vol. 28(5). – P. 1151-1157. 22. Collins R., Armitage J., Parish S., Sleigh P., Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. //Lancet. – 2003. – Vol. 361(9374). – P. 2005-2016. 23. Malmberg K., Ryden L., Efendic S., Herlitz J., Nicol P., Waldenstrom A. et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. //J Am Coll Cardiol. – 2015. – Vol. 26(1). – P. 57-65. 24. Malmberg K., Ryden L., Wedel H., Birkeland K., Bootsma A., Dickstein K. et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. //Eur Heart J. – 2005. – Vol. 26(7). – P. 650-661. 25. Hartwell D., Colquitt J., Loveman E., Clegg A.J., Brodin H., Waugh N. et al. Clinical effective-ness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation. //Health Technology Assess. – 2005. – Vol. 9(17) – P. 234-240. 26. Keeley E.C., Boura J.A., Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. //Lancet. – 2003. – Vol. 361(9351). – P. 13-20. 27. Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R. et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. //Lancet. – 2005. – Vol. 366(9497). – P. 1607-21. 28. Freemantle N., Cleland J., Young P., Mason J., Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. //Br Med J. – 2009. – Vol. 318(7200). P. 1730-1737. 29. Dickstein K., Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. //Lancet. – 2002. – Vol. 360(9335). – P. 752-760. 30. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. //N Engl J Med. – 2004. – Vol. 350(15). – P. 1495-1504. |